SCHEMBL9984499

SCHEMBL9984499

NC(=O)C1CCN(c2ccc(N)cc2F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
ALDH1A1 P00352 4/20 0.52
GFER P55789 2/20 0.52
LMNA P02545 2/20 0.52
MAPK1 P28482 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
POLB P06746 1/20 0.49
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
THRB P10828 1/20 0.47
ALOX15 P16050 1/20 0.47
YWHAG P61981 1/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9987978 0.88 MAPT (0.56) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL9984155 0.83 GAA (0.52) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL2556324 0.82 ALDH1A1 (0.62) MAPTALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL29507892 0.81 MAPT (0.58) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL854063 0.81 MAPT (0.58) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL25172818 0.81 MAPT (0.46) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL17264125 0.81 MAPT (0.61) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL14804173 0.81 GAA (0.50) MAPTALDH1A1TDP1CYP1A2CYP3A4
SCHEMBL9984131 0.80 ALDH1A1 (0.75) MAPTALDH1A1LMNATDP1CYP1A2
SCHEMBL12074106 0.80 ALDH1A1 (0.59) MAPTALDH1A1GFERLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US disclosed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME NOS3, PTMS, NOS2 MAPT 4055/4885ALDH1A1 2401/4885GFER 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.